Alden M. Landry, MD, MPH, Rose L. Molina, MD, MPH, Regan Marsh, MD, MPH, Emma Hartswick, Raquel Sofia Sandoval, Nora Osman, MD, and Leonor Fernandez, MD
Adapting content in response to new science is common, but educators can struggle to offer current questions that matter to students.
AMA J Ethics. 2021;23(2):E127-131. doi:
10.1001/amajethics.2021.127.
When police officers and clinicians perceive a moral transgression committed by an agent responding to risk in the field, they are susceptible to moral injury.
AMA J Ethics. 2022;24(2):E126-132. doi:
10.1001/amajethics.2022.126.
Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
Carmen Black Parker, MD, Amanda Calhoun, MD, MPH, Ambrose H. Wong, MD, MSEd, Larry Davidson, PhD, and Charles Dike, MBChB, MPH
Psychiatric emergencies, coping stress reactions, and iatrogenic injuries are not responded to with the same vigor as acute medical decompensation. That needs to change.
AMA J Ethics. 2020;22(11):E956-964. doi:
10.1001/amajethics.2020.956.